mas suggests a possible relationship between ophthalmic melanocytoma and other ophthalmic melanocytic neoplasms. BAP1 mutation may accompany the transformation of ophthalmic melanocytoma to melanoma.
Investigation of Somatic GNAQ, GNA11, BAP1 and SF3B1 Mutations in Ophthalmic Melanocytomas

Introduction
In the 1960s, Dr. Lorenz E. Zimmerman made some important observations regarding ophthalmic melanocytoma, asserting that due to its nonmetastasizing nature, this benign lesion could be observed and the eye saved from enucleation [1] . He also postulated a histopathologic similarity to ocular melanocytosis and suggested that melanocytoma may have a clinical presentation analogous to cutaneous blue nevi [2] . Previous work has revealed mutations in GNAQ/11 as a genetic basis shared between a case of melanosis oculi and blue nevi [3] , and recent work by Mudhar et al. [4] demonstrates the same genetic alteration in ciliochoroidal melanocytoma, thereby suggesting a genetic link between these three benign, pigmented ophthalmic entities.
Our published knowledge of genetic mutations in ophthalmic melanocytoma consists of 2 cases, both of which were ciliochoroidal in location and established by mutational analysis of a single exon in three target genes ( GNAQ , GNA11 and BRAF ) [4] . The unavailability of enucleated melanocytoma specimens (which may ironically be a result of Dr. Zimmerman's original work) contributes to the absence of information about the genetic events underlying the lesional pathogenesis.
Here, we present our findings describing the genetic analysis of 6 ophthalmic melanocytoma samples (1 iridociliary and 5 optic nerve) using targeted exome sequencing for GNAQ/11, BAP1 and SF3B1 . This method is unique in that it sequences the entire gene (exons) and can identify both common and rare mutations in addition to other alterations such as copy number gains and losses [5] . This methodology, developed at the Memorial Sloan-Kettering Cancer Center, has become the standard technique by which all tumors are evaluated at our institution.
Methods
At the participating institutions, melanocytoma specimens were retrieved from the archives of the department of pathology. The specimens were obtained through a search of the respective database, patient and tissue records. A diagnosis of melanocytoma was confirmed by each institution's respective ophthalmic pathologist prior to inclusion in the study. Cytogenetic analysis by fluorescence in situ hybridization was performed for the specimens (No. 4 and 6) that had malignantly transformed to melanoma, by a method that has previously been reported [6] . Chromosome number variation was also evaluated with the IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) assay for all specimens. The iridociliary specimen was obtained through a needle biopsy, and the reason for enucleation of the remaining specimens is depicted in table 1 .
Isolation and Purification of DNA
Microdissection was performed on the 5 formalin-fixed and paraffin-embedded (FFPE) samples on 10-μm-thick unstained sections, employing hematoxylin and eosin-stained (HE) sections when needed as a guide. This included a malignantly transformed melanocytoma (No. 4), which was submitted entirely, without distinction between benign-and malignant-appearing areas. The remaining specimen (No. 6) was biopsied from the original lesion and snap frozen in liquid nitrogen at the time of enucleation and stored at -80 ° C. Prior to freezing, this specimen was dissected into melanoma and melanocytoma with the assistance of a microscope. However, without the guidance of HE sections, it is difficult to know whether these were true representations of benign and malignant tumors. These two parts of the specimens had an identical genetic signature and were therefore reported together. The DNeasy Tissue Kit (Qiagen) was used for DNA extraction according to the manufacturer's recommendations. The Nano-Drop 8000 (Thermo Scientific) and Qubit (Life Technologies) devices were employed to quantify the extracted DNA. The minimum concentration of FFPE DNA is 250 ng. Exon Capture Sequencing Genetic alterations in GNAQ/11, BAP1 and SF3B1 were profiled using the IMPACT assay. As previously described in detail [5] , this assay employs solution-phase hybridization-based exon capture and massively parallel DNA sequencing to interrogate all proteincoding exons and select introns of 279 oncogenes, tumor suppressor genes and members of pathways considered actionable by targeted therapies. The concentration of genomic DNA and DNA sequence library are both tested at the beginning of the assay before and after exon capture. If the yield is too low at any of these steps, the sample is failed. None of the specimens in this study failed these steps.
In brief, barcoded sequence libraries (New England Biolabs, Kapa Biosystems) underwent exon capture by hybridization (Nimblegen SeqCap) using a custom probe design, with approximately 112-250 ng of DNA used as input for library construction and 100 ng of the library used as input for exon capture [7] . To prevent off-target hybridization, a pool of blocker oligonucleotides, complementary to the full sequences of all barcoded adaptors, was spiked into a final total concentration of 10 mmol/l. An Illumina HiSeq 2000 device was used to sequence DNA and generate paired-end 75-bp reads. The reads were aligned to the reference human genome (hg19) using the Burrows-Wheeler alignment tool [8] , and local realignment and quality score recalibration were completed using the Genome Analysis Toolkit (GATK) according to GATK best practices [9] . A mean unique-sequence coverage of ×281 was achieved. Single-nucleotide variants were identified using muTect [10] . For specimens without matched normal DNA, all silent variants and all single-nucleotide polymorphisms vali- 174 dated by the 1,000 Genomes Project were filtered out. Indels were detected using the SomaticIndelDetector tool in GATK, and the Integrative Genomics Viewer was used to manually review all candidate mutations and indels [11] .
Results
In this collection of 6 (1 iridociliary and 5 optic-nerve) ophthalmic melanocytoma specimens, two mutations were detected in GNAQ in codon 209 (Gln209Leu). They occurred in 1 iridociliary melanocytoma ( fig. 1 ) and 1 of the optic-nerve melanocytomas ( fig. 2 ). The 2 specimens in which the melanocytoma had clinically and histopathologically transformed to a melanoma contained a mutation in BAP1 . The mutational analysis of the 6 specimens is summarized in table 1 . No specimen had a mutation in SF3B1 .
Copy number variations were identified in specimen 6 and revealed a loss of chromosome 1 and chromosome 3 and a gain of chromosome 8. For the remaining 5 specimens, the analysis did not reveal any significant amplifications or deletions. Specimens 4 and 6 were monosomy 3 by fluorescence in situ hybridization. No patient developed metastases over a median follow-up of 5.8 years, and both patients with malignantly transformed melanocytomas are still alive.
Specimen 6 was grossly dissected into melanoma and melanocytoma and snap frozen at the time of enucleation. Both the melanocytoma and melanoma specimens were found to have a mutation in GNAQ and BAP1 , but the patient-matched normal tissue had neither, confirming that these mutations were likely somatic.
Discussion
Despite the clinical and histopathological differences, molecular studies show an overlap with morphologically distinct lesions, namely blue nevi, melanocytoma, ophthalmic melanocytosis and uveal nevi/melanomas. The IMPACT assay employed in this study has the advantage of providing a combination approach for the detection of multiple categories of genetic alterations [7] . It gives us the advantage of investigating the entire exons of GNAQ/11, BAP1 and SF3B1 for both the common and rare mutations as well as identifying additional genomic alterations such as copy number losses and gains [5] .
Using this method, we discovered the presence of a Q209L exon 5 GNAQ mutation in the iridociliary melanocytoma and in 1 of 5 of the optic-nerve melanocytomas. It is unclear whether these findings are representative of all melanocytomas or just of those that come to enucleation due to aggressive clinical features. The reasons for detecting mutations in only 2 out of 6 melanocytomas include a lower prevalence of mutation in melanocytoma, the small sample size of this study or, less likely, the presence of low allele frequency mutations that could have been missed due to low tumor purity or subclonality.
Somatic mutations are typically mutually exclusive in either GNAQ or GNA11 . They have been revealed in a number of melanocytic neoplasms, including 83% of all uveal melanomas (including 22% of the iris melanomas), 90% of the uveal melanoma metastases, choroidal nevi, blue nevi (skin and oral cavity), oculodermal melanocytosis, and central nervous system and ciliochoroidal melanocytomas [3, [12] [13] [14] [15] [16] [17] [18] [19] ( table 2 ) . The present study indicates that ophthalmic melanocytomas of the iridociliary body and optic nerve can be added to this list. It has been proposed that lesions with GNAQ/11 mutations may have two common traits: (1) they occur in extraepithelial melanocytes such as the leptomeninges, uvea and dermis, and (2) they appear to arise preferentially in melanocytes derived from cranial (rather than truncal) neural crests [15] . Our findings of mutations in iridociliary and optic-nerve melanocytomas could be consistent with both characteristics, since both are extraepithelial. Furthermore, the iris stroma and melanocytes of the optic nerve originate from melanocytes derived from cranial neural crest precursors (either the leptomeninges, lamina fusca or choroid).
GNAQ/11 mutations may be detected in uveal melanoma development but are not considered sufficient for malignant transformation [3] . Because 84% of all metastasizing uveal melanoma tumors have inactivating somatic mutations in BAP1 (BRCA1-associated protein 1), BAP1 is implicated as a later aberration and an associated event in uveal melanoma metastasis [20] . Malignant transformation is the most likely indication for removal of a melanocytoma-containing eye. In this study, 2 optic nerve melanocytomas with clinically suspected and histopathologically confirmed transformation to melanoma revealed a BAP1 mutation. These mutations consisted of a nonsense mutation (R385 * ) and a frameshift insertion (D663fs). A germline nonsense mutation has been found at the same location in a family with uveal melanoma; and while this specific frameshift mutation has not been previously reported, alterations at the nuclear localization signal domain have been previously found [21] .
This suggests that mutations in BAP1 may accompany the malignant transformation of ophthalmic melanocytoma to melanoma. In this study, it is unclear whether the BAP1 mutation existed exclusively in the malignantly transformed portion of the melanocytoma, or whether it was also present in the benign-appearing melanocytoma. Despite our small sample size, future confirmation of this discovery could suggest the need for aggressive management of ophthalmic melanocytomas (and any benign-appearing melanocytic lesion), for instance, in patients carrying a known germline mutation in BAP1 . If confirmed in larger numbers of samples, it may be an option to biopsy suspicious melanocytomas for the presence of a somatic BAP1 mutation.
Mutations in SF3B1 have recently been identified in approximately [15] [16] [17] [18] .6% of all uveal melanomas; they are associated with good prognosis and rarely occur coincidentally with BAP1 mutations [22] [23] [24] . None of the melanocytoma specimens in this study, including those without BAP1 mutations, had an SF3B1 mutation.
A collection of melanocytic neoplasms, mainly extradermal and of neural-crest derivation, possesses alterations in GNAQ/11 , and this study demonstrates that ophthalmic melanocytomas of the iridociliary body and optic nerve can be added to this list.
